



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. |
|-----------------|-------------|----------------------|---------------------|------------------|
| 08/908,867 | 08/08/1997 | ANDREW A. YOUNG | 227/166 | 9959 |

44638 7590 01/20/2005
ARNOLD & PORTER LLP (18528)
555 TWELFTH ST, NW
WASHINGTON, DC 20004

EXAMINER

CANELLA, KAREN A

ART UNIT PAPER NUMBER

1642

DATE MAILED: 01/20/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

Requested copy attached.

LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S
INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

ATTY. DOCKET NO.
227/166SERIAL NO.
08/908,867APPLICANT:
Andrew Young et al.FILING DATE:
August 8, 1997GROUP:
1642

U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB CLASS | FILING DATE |
|---------------------|-----------------|----------|-----------------|-------|--------------|----------------|
| ALH | 5,264,372 | 11/23/93 | Beaumont et al. | | | |
| ALH | 5,424,286 | 06/13/95 | Eng | | | |

FOREIGN PATENT DOCUMENTS

| EXAMINER INITIAL | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB CLASS | TRANSLATION | |
|---------------------|-----------------|----------|---------|-------|--------------|-------------|----|
| | | | | | | YES | NO |
| ALH | WO 95/07098 | 16.03.95 | PCT | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

| | |
|-----|---|
| ALH | Daniel et al. "Use of Glucagon in the Treatment of Acute Diverticulitis," <i>Br. Med. J.</i> , 3:720, 1974 |
| ALH | D'Alessio et al. "Elimination of the Action of glucagon-like Peptide 1 Causes an Impairment of glucose tolerance after Nutrient Ingestion by Healthy Baboons," <i>J. Clin. Invest.</i> , 97:133-38, 1996 |
| ALH | Eissele et al. "Rat Gastric somatostatin and Gastrin Release: Interactions of Exendin-4 and Truncated Glucagon-Like Peptide-1 (GLP-1) Amide," <i>Life Sci.</i> , 55:629-34, 1994 |
| ALH | Eng et al. "Purification and Structure of Exendin-3, a New Pancreatic Secretagogue Isolated from <i>Heloderma horridum</i> Venom," <i>J. Biol. Chem.</i> , 265:20259-62, 1990 |
| ALH | Eng et al. "Isolation and Characterization of Exendin-4, an Exendin-3 Analogue, from <i>Heloderma suspectum</i> Venom", <i>J. Biol. Chem.</i> , 267:7402-05, 1992 |
| ALH | Fehmann et al. "Stable Expression of the Rat GLP-I Receptor in CHO Cells: Activation and Binding Characteristics Utilizing GLP-I(7-36)-Amide, Oxyntomodulin, Exendin-4, and Exendin(9-39)," <i>Peptides</i> 15 (3): 453-6, 1994 |
| ALH | Ferguson et al. "Cell-Surface Anchoring of Proteins Via Glycosylphosphatidylinositol Structures", <i>Annu. Rev. Biochem.</i> 57:285-320, 1988 |
| ALH | Glauser et al. "Intravenous glucagon in the Management of Esophageal Food Obstruction", <i>J. Am. Coll. Emergency Physns</i> , 8:228, 1979 |
| ALH | Gedulin et al. "Comparison of Effects of Amylin, Glucagon-like Peptide-1 and Exendin-4 to Inhibit Pentagastrin-Stimulated Gastric Acid Secretion," <i>Diabetologia</i> , 40 (Suppl. 1):A300 (Abstract 1181) (1997) 8:228, 1979 |
| ALH | Goke et al. "Exendin-4 Is a High Potency Agonist and Truncated Exendin-(9-39)-amide an Antagonist at the Glucagon-like Peptide 1-(7-36)-amide Receptor of Insulin-secreting β -Cells", <i>J. Biol. Chem.</i> , 268:19650-55, 1993 |

EXAMINER:

Anne L. Holleran

DATE CONSIDERED:

12/13/00

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S
INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

ATTY. DOCKET #

227/166

SERIAL NO.

08/908,867

APPLICANT:

Andrew Young et al.

FILING DATE:

August 8, 1997

GROUP:

1642

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

| | | |
|-----|--|---|
| ALH | | Kolligs et al. "Reduction of the Incretin effect in Rats by the Glucagon-Like Peptide 1 Receptor antagonist Exendin(9-39) Amide", <i>Diabetes</i> , 44:16-19, 1995 |
| ALH | | Malhotra et al. "Exendin-4, a new peptide from <i>Heloderma suspectum</i> venom, potentiates cholecystokinin-induced amylase release from rat pancreatic acini", <i>Regulatory Peptides</i> , 41:149-56, 1992 |
| ALH | | Montrose-Rafizadeh et al. "Structure-function Analysis of Exendin-4 / GLP-1 Analogs", <i>Diabetes</i> , 45(Suppl. 2):152A, 1996 |
| ALH | | O'Halloran et al. "Glucagon-like peptide-1 (7-36)-NH ₂ : a physiological inhibitor of gastric acid secretion in man," <i>J. Endocrinol.</i> 126 (1): 169-73, 1990 |
| ALH | | Orskov et al. "Biological Effects and Metabolic Rates of Glucagonlike Peptide-1 7-36 Amide and glucagonlike Peptide-1 7-37 in Healthy Subjects Are Indistinguishable", <i>Diabetes</i> , 42:658-61, 1993 |
| ALH | | Raufman et al. "Truncated Glucagon-like Peptide-1 Interacts with Exendin Receptors in Dispersed Acini from Guinea Pig Pancreas", <i>J. Biol. Chem.</i> 267:21432-37, 1992 |
| ALH | | Raufman et al. "Exendin-3, a Novel Peptide from <i>Heloderma horridum</i> Venom, Interacts with Vasoactive Intestinal Peptide Receptors and a Newly Described Receptor on dispersed Acini from Guinea Pig Pancreas," <i>J. Biol. Chem.</i> 266:2897-902, 1991 |
| ALH | | Scarpignato et al. "Action of Caerulein on gastric emptying of the Conscious Rat", <i>Arch. Int. Pharmacodyn. Ther.</i> 246:286-94 1980 |
| ALH | | Schepp, et al. "Exendin-4 and exendin-(9-39)NH ₂ : agonist and antagonist, respectively, at the rat parietal cell receptor for glucagon-like peptide-1-(7-36)NH ₂ ," <i>Eur. J. Pharm.</i> 269:183-91, 1994 |
| ALH | | Schjoldager et al. "GLP-1 (Glucagon-like Peptide 1) and Truncated GLP-1, Fragments of Human Proglucagon, Inhibit Gastric Acid Secretion in Humans," <i>Dig. Dis. Sci.</i> 34 (5): 703-8, 1989 |
| ALH | | Singh et al. "Use of ¹²⁵ I-[Y ³⁹]exendin-4 to characterize exendin receptors on dispersed pancreatic acini and gastric chief cells from guinea pig," <i>Regul. Pept.</i> 53:47-59, 1994 |
| ALH | | Stower et al. "A trial of glucagon in the treatment of painful biliary tract disease," <i>Br. J. Surg.</i> , 69:591-2, 1982 |
| ALH | | Thorens et al. "Cloning and Functional Expression of the Human Islet GLP-1 Receptor," <i>Diabetes</i> 42 (11): 1678-82, 1993 |
| ALH | | Thorens, "Expression cloning of the pancreatic β cell receptor for the gluco-incretin hormone glucagon-like peptide 1," <i>Proc. Natl. Acad. Sci. USA</i> 89:8641-45, 1992 |
| ALH | | Wang et al. "Glucagon-like Peptide-1 Is a Physiological Incretin in Rat," <i>J. Clin. Invest.</i> , 95:417-21, 1995 |
| ALH | | Wang, Y.J. and Hanson, M.A. "Parenteral Formulations of Proteins and Peptides: Stability and Stabilizers," <i>Journal of Parenteral Science and Technology</i> , Technical Report No. 10, Supp. 42:2S, 1988 |
| ALH | | Wettergren et al. "Truncated GLP-1 (Proglucagon 78-107-Amide) Inhibits Gastric and Pancreatic Functions in Man," <i>Dig. Dis. Sci.</i> 38 (4): 665-73, 1993 |

EXAMINER:

Anne L. Holliman

DATE CONSIDERED:

12/13/80

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S
INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

ATTY. DOCKET #
227/166SERIAL NO.
08/908,867APPLICANT:
Andrew Young et al.FILING DATE:
August 8, 1997GROUP:
1642

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

| | | |
|----|--|--|
| 24 | | Willms et al. "Gastric Emptying, Glucose Responses, and Insulin Secretion after a Liquid Test Meal: Effects of Exogenous Glucagon-Like Peptide-1 (GLP-1)-(7-36) Amide in Type 2 (Noninsulin-Dependent) Diabetic Patients," J. Clin. Endocrinol. Metab. 81(1):327-32 1996 |
|----|--|--|

BOOKS

| | | |
|--|--|---|
| | | Cohen, S.A., Meys, M., and Tarrin, T.L. (1989), The Pico Tag Method: A Manual of Advanced Techniques for Amino Acid Analysis, pp. 11-52; Millipore Corporation, Milford, MA). |
| | | Introduction to Cleavage Techniques, Applied Biosystems, Inc., 1990, pp. 6-12. |
| | | Sambrook, et al.; Molecular Cloning: A Laboratory Manual, 2d Ed., Cold Spring Harbor 1989. |

EXAMINER:

Anne L. Holleran

DATE CONSIDERED: 12/13/00

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Please type a plus sign (+) inside this box → +

APR 15 2002

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

Complete if Known

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

| | |
|------------------------|------------------|
| Application Number | 08/908,867 |
| Filing Date | August 8, 1997 |
| First Named Inventor | Young |
| Group Art Unit | 1642 |
| Examiner Name | Holleran |
| Attorney Docket Number | 030639.0040.CIP1 |

Sheet 1 of 2

U.S. PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | U.S. Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|--------------------|-----------------------|----------------------|-----------------------------------|---|--|---|
| | | Number | Kind Code ² (if known) | | | |
| | | | | | | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁴ |
|--------------------|-----------------------|-------------------------|---------------------|-----------------------------------|---|--|---|----------------|
| | | Office ³ | Number ⁴ | Kind Code ² (if known) | | | | |
| KAC | 5 | WO | 98/30231 | | Amylin Pharmaceuticals, Inc. | 07-16-1998 | | |
| KAC | 6 | WO | 99/07404 | | Amylin Pharmaceuticals, Inc. | 02-18-1999 | | |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁷ |
|--------------------|-----------------------|--|----------------|
| KAC | 1 | BAYER et al., "Advances in Poison Management," <u>Clin. Chem.</u> , 42(8)(B):1361-66 (1996) | |
| | 2 | D'ALESSIO et al., "Glucagon-like Peptide 1 Enhances Glucose Tolerance Both by Stimulation of Insulin Release and by Increasing Insulin-independent Glucose Disposal," <u>J. Clin. Invest.</u> , 93:2263-66 (1994) | |
| | 3 | HOLST, "Glucagonlike Peptide-1: A Newly Discovered Gastrointestinal Hormone," <u>Gastroenterology</u> , 107:1848-55 (1994) | |
| | 4 | LAWLER et al., "Comparison of Effects of Amylin, Glucagon-like Peptide-1 (GLP-1) and Exendin-4 to Inhibit Pentagastrin-Stimulated Gastric Acid Secretion in Rats," <u>Gastroenterology</u> , 112(4):A194, (1997) | |

Examiner Signature

James D. Gamella

Date Considered

12/9/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

[illegible]


Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete If Known

Application Number 08/908,867
Filing Date April 10, 2002
First Named Inventor Young
Group Art Unit 1642
Examiner Name Holleran
Attorney Docket Number 030639.0040.CPA1

RECEIVED

JAN 06 2003

TECH CENTER 1600/2800

Sheet 1 of 2

U.S. PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | U.S. Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|-----------------------|--------------------------|----------------------|--------------------------------------|--|--|--|
| | | Number | Kind Code ² (if known) | | | |
| | | | | | | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ³ |
|-----------------------|--------------------------|-------------------------|---------------------|--------------------------------------|--|--|--|----------------|
| | | Office ² | Number ² | Kind Code ² (if known) | | | | |
| KAL | | WO | 98/05351 | | Amylin Pharmaceuticals, Inc. | 02-12-1998 | | |
| | | | | | | | | |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ³ |
|-----------------------|--------------------------|--|----------------|
| KAL | | NAVARRO, M. et al., "Colocalization of Glucagon-Like Peptide-1 (GLP-1) Receptors, Glucose Transporter GLUT-2, and Glucokinase mRNAs in Rat Hypothalamic Cells: Evidence for a Role of GLP-1 Receptor Agonists as an Inhibitory Signal for Food and Water Intake," <u>Journal of Neurochemistry</u> , 67:1982-1991 (1996) | |
| | | | |
| | | | |
| | | | |

| | | | |
|-----------------------|------------------|--------------------|---------|
| Examiner Signature | Karen A. Gamella | Date Considered | 12/9/03 |
|-----------------------|------------------|--------------------|---------|

*EXAMINER: Initials if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.